MDPI and ACS Style
Kim, J.H.; Nam, H.-C.; Kim, C.-W.; Cho, H.S.; Yoo, J.-S.; Han, J.W.; Jang, J.W.; Choi, J.Y.; Yoon, S.K.; Yang, H.;
et al. Comparative Analysis of Atezolizumab Plus Bevacizumab and Hepatic Artery Infusion Chemotherapy in Unresectable Hepatocellular Carcinoma: A Multicenter, Propensity Score Study. Cancers 2023, 15, 4233.
https://doi.org/10.3390/cancers15174233
AMA Style
Kim JH, Nam H-C, Kim C-W, Cho HS, Yoo J-S, Han JW, Jang JW, Choi JY, Yoon SK, Yang H,
et al. Comparative Analysis of Atezolizumab Plus Bevacizumab and Hepatic Artery Infusion Chemotherapy in Unresectable Hepatocellular Carcinoma: A Multicenter, Propensity Score Study. Cancers. 2023; 15(17):4233.
https://doi.org/10.3390/cancers15174233
Chicago/Turabian Style
Kim, Ji Hoon, Hee-Chul Nam, Chang-Wook Kim, Hee Sun Cho, Jae-Sung Yoo, Ji Won Han, Jeong Won Jang, Jong Young Choi, Seung Kew Yoon, Hyun Yang,
and et al. 2023. "Comparative Analysis of Atezolizumab Plus Bevacizumab and Hepatic Artery Infusion Chemotherapy in Unresectable Hepatocellular Carcinoma: A Multicenter, Propensity Score Study" Cancers 15, no. 17: 4233.
https://doi.org/10.3390/cancers15174233